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The clonality of a random sample of 102 invasive pneumococcal serotype 3 strains 
isolated from Gauteng Province during January 2000 to December 2003 was 
investigated. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing 
(MLST) revealed a heterogeneous population with several PFGE clusters and 
sequence types (STs). The largest PFGE cluster comprised 36/102 (35%) isolates 
including seven that belonged to ST458, a clone that is not common in other parts of 
the world. The global clone (ST180) which is common in the United States and other 
countries was found in a cluster that represented only 14/102 (14%) of isolates 
examined.  
 
The first multidrug-resistant pneumococcal serotype 19A strain that was isolated in 
South Africa in 1977 was compared with invasive serotype 19A multidrug-resistant 
strains isolated in South Africa during June 1999 to December 2004. PFGE analysis 
of these isolates demonstrated clonal diversity among the isolates. MLST of 16 
randomly selected isolates revealed several STs, none of which was the same ST as 
the 1977 clone.  
 
Both serotype 3 and 19A were not associated with increased mortality or HIV 
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